

DONEGAL GROUP INC  
Form 8-K  
October 19, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 19, 2017**

**Donegal Group Inc.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b> <b>(State or other jurisdiction</b>	<b>0-15341</b> <b>(Commission</b>	<b>23-02424711</b> <b>(I.R.S. employer</b>
<b>of incorporation)</b>	<b>file number)</b>	<b>identification no.)</b>

<b>1195 River Road, Marietta, Pennsylvania</b> <b>(Address of principal executive offices)</b>	<b>17547</b> <b>(Zip code)</b>
<b>Registrant's telephone number, including area code: 717-426-1931</b>	

**Not Applicable**

**(Former name or former address, if changed since last report)**

Edgar Filing: DONEGAL GROUP INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Information.**

On October 19, 2017, Donegal Mutual Insurance Company ( Donegal Mutual ), the holder of majority voting control of the Registrant, announced that its chief executive officer, Donald H. Nikolaus, has taken a temporary medical leave of absence.

The board of directors of Donegal Mutual named Kevin G. Burke, president and chief executive officer of Donegal Group Inc., to serve as acting chief executive officer of Donegal Mutual during Mr. Nikolaus leave of absence.

The boards of directors of several of the Registrant s subsidiaries for which Mr. Nikolaus serves as president and chief executive officer named Mr. Burke to serve as acting chief executive officer of those subsidiaries during Mr. Nikolaus leave of absence.

**Item 9.01. Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Exhibit Description</b>
99.1	<u>Donegal Mutual press release dated October 19, 2017</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DONEGAL GROUP INC.

By: /s/ Jeffrey D. Miller  
Jeffrey D. Miller, Executive Vice

President and Chief Financial Officer

Date: October 19, 2017

ained in the License Agreement.

Under the terms of the License Agreement, neither party may assign the License Agreement without the prior written consent of the other party, except to its affiliates; however, either party must assign the License Agreement in connection with the sale of all or substantially all of its assets (whether by merger, consolidation or otherwise).

In addition to the foregoing, the License Agreement contains certain terms and provisions regarding the Company's ongoing litigation with Genzyme Corporation as well as customary terms and conditions, including, but not limited to, provisions related to confidentiality, record storage and intellectual property.

The foregoing description of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the License Agreement which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

On December 21, 2011, the Company issued a press release concerning the License Agreement, which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

10.1 License Agreement, dated as of December 21, 2011, by and between Anika Therapeutics, Inc. and DePuy Mitek, Inc.\*

99.1 Press Release of Anika Therapeutics, Inc., dated December 21, 2011.

\* Confidential treatment has been requested for certain provisions of this Exhibit pursuant to Rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anika Therapeutics, Inc.

Date: December 22, 2011

By: /s/ Kevin W. Quinlan  
Name: Kevin W. Quinlan  
Title: Chief Financial Officer